Samy C.
- Country
- France
- Department
- Hématologie Clinique et Oncologie Médicale
Research Overview
- An ALFA 2101 multicenter randomized phase II study: CPX-351 versus intensive chemotherapy in patients with de novo intermediate or adverse risk AML stratified by genomics
- Phase 3 Study of Idarubicin, Daunorubicin, Cytarabine, and Mycophenolic Acid in Acute Myeloid Leukemia Patients Aged 18-60
- Phase II Study on Efficacy and Safety of Tagraxofusp and Venetoclax in Treatment-Naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients
Data & Insights
Has run more than one trial at 36 of 66 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in the treatment of acute myeloid leukemia (AML), with particular focus on adult patients aged 18 to 60. Their research encompasses innovative therapeutic approaches for both newly diagnosed and challenging cases of AML.
- De novo AML treatment strategies
- Intermediate and adverse risk AML management
- Genomic stratification in leukemia
Therapeutic Innovations
The investigator's work focuses on comparing different therapeutic regimens including high-dose idarubicin and daunorubicin treatments. Their expertise extends to evaluating various dosing strategies of cytarabine in consolidation therapy.
- Advanced chemotherapy protocols
- Novel drug combinations
- Treatment response assessment
Transplant Medicine
The investigator has extensive experience in allograft procedures and graft versus host disease (GvHD) prevention. Their research includes evaluation of mycophenolic acid as prophylaxis in transplant patients.
- GvHD prevention strategies
- Post-transplant care
- Remission maintenance
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.